FDA OKs Anxiety Stimulation Device; Long-Term KarXT Data; Psilocybin Adverse Events

The FDA cleared Modius Stress, a non-invasive electrical stimulation device used to treat generalized anxiety disorder, said maker Neurovalens.

Youth with mood disorders were 30% less likely to acquire a driver’s license than those without. They also had significantly higher rate of crashes, moving violations, and license suspensions. (JAMA Network Open)

Investigational xanomeline-trospium (KarXT) for schizophrenia showed long-term improvement in symptoms without weight gain, Bristol Myers Squibb announced. At the 1-year mark, over 75% of patients achieved at least a 30% improvement in symptoms from baseline.

It’s been 50 years since the American Psychiatric Association voted that homosexuality should no longer be considered a mental illness. (NBC News)

First-degree relatives of individuals with treatment-resistant depression had more than a ninefold higher risk for also developing such depression, according to a study of Taiwanese families. (JAMA Psychiatry)

A European Medicine Agency committee will meet this week to discuss suicidal ideation and GLP-1 receptor agonists. (Reuters)

Five adverse events — headache, nausea, anxiety, dizziness, and elevated blood pressure — were commonly reported across studies testing a single therapeutic dose of psilocybin, though most were tolerable and resolved within 2 days. (JAMA Network Open)

One man described how his dog helps him cope with certain schizophrenia symptoms like self-harm and hallucinations. (USA Today)

In recent years, more and more dogs are getting antidepressant scripts for their anxiety. (STAT)

The rate of teen drug use may be at the lowest it’s been in decades, the director of the National Institute on Drug Abuse told the New York Times.

As online sports betting has boomed, so have calls to gambling addiction hotlines. (NBC News)

Please enable JavaScript to view the

comments powered by Disqus.